ISHLT Voices: Bronchiolitis Obliterans Syndrome Part III, Presented by Zambon USA

Published 15 November 2023
  • Advanced Lung Failure & Transplantation
  • Industry
  • ISHLT Voices
  • News
  • Nursing & Allied Health
  • Podcast
  • Publications & Journals
  • Pulmonology

Experts Tackle Bronchiolitis Obliterans Syndrome Part III:
Differentiating Phenotypes and Current Gaps, and Emerging Treatment Strategies

Presented by Zambon USA

ISHLT voices logoPart three in this ISHLT Voices podcast series of “Experts Tackle Bronchiolitis Obliterans Syndrome (BOS)”, presented by Zambon USA, explores bronchiolitis obliterans syndrome (BOS) and takes a deep dive into CLAD phenotype differentiation, current gaps in diagnosis and management of BOS, emerging treatment strategies, and finally, discuss the advances made in BOS diagnosis and management over the last decade.

Listen Now

In this episode, leading investigators from the Alberta Transplant Applied Genomics Centre (ATAGC), Drs. Phil Halloran, Kieran Halloran, and Patrick Gauthier will walk you through their efforts in the TRIFECTA series of studies to triangulate insights from dd-cfDNA, molecular diagnostics, and donor specific antibody versus standard histological assessments in heart, lung, and kidney transplantation.

Headshot of Steven Hays
Stephen Hays, MD

Medical Director, Advanced Lung Disease and Lung Transplant Programs
University of California San Francisco
San Francisco, CA USA

Headshot of Justin Rosenheck
Justin P. Rosenheck, DO

Clinical Assistant Professor of Internal Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
Lung Transplant Program
The Ohio State University Wexner Medical Center
Columbus, OH USA

Listen now to hear Drs. Hays and Rosenheck discuss these important topics regarding the future of BOS. Click the button below to listen—or subscribe on the podcast platform of your choice. 

Listen Now

This episode was created for ISHLT Voices and sponsored by Zambon USA, Ltd.

The content of this podcast was developed entirely by our industry partner, Zambon . It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.